Raquela J Thomas, Mee Y Bartee, Miriam Valenzuela-Cardenas, Eric Bartee
{"title":"溶癌性粘液瘤病毒在癌症三阴性小鼠模型中是有效的,尽管感染率很低。","authors":"Raquela J Thomas, Mee Y Bartee, Miriam Valenzuela-Cardenas, Eric Bartee","doi":"10.1016/j.omto.2023.08.014","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic viruses are being heavily investigated as novel methods to treat cancers; however, predicting their therapeutic efficacy remains challenging. The most commonly used predictive tests involve determining the <i>in vitro</i> susceptibility of a tumor's malignant cells to infection with an oncolytic agent. Whether these tests are truly predictive of <i>in vivo</i> efficacy, however, remains unclear. Here we demonstrate that a recombinant, oncolytic myxoma virus shows efficacy in two murine models of triple negative breast cancer despite extremely low permissivity of these models to viral infection. These data demonstrate that <i>in vitro</i> infectivity studies are not an accurate surrogate for therapeutic efficacy and suggest that other tests need to be developed.</p>","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/3e/main.PMC10507476.pdf","citationCount":"0","resultStr":"{\"title\":\"Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection.\",\"authors\":\"Raquela J Thomas, Mee Y Bartee, Miriam Valenzuela-Cardenas, Eric Bartee\",\"doi\":\"10.1016/j.omto.2023.08.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Oncolytic viruses are being heavily investigated as novel methods to treat cancers; however, predicting their therapeutic efficacy remains challenging. The most commonly used predictive tests involve determining the <i>in vitro</i> susceptibility of a tumor's malignant cells to infection with an oncolytic agent. Whether these tests are truly predictive of <i>in vivo</i> efficacy, however, remains unclear. Here we demonstrate that a recombinant, oncolytic myxoma virus shows efficacy in two murine models of triple negative breast cancer despite extremely low permissivity of these models to viral infection. These data demonstrate that <i>in vitro</i> infectivity studies are not an accurate surrogate for therapeutic efficacy and suggest that other tests need to be developed.</p>\",\"PeriodicalId\":18869,\"journal\":{\"name\":\"Molecular Therapy Oncolytics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/3e/main.PMC10507476.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Therapy Oncolytics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.omto.2023.08.014\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/21 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy Oncolytics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omto.2023.08.014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/21 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection.
Oncolytic viruses are being heavily investigated as novel methods to treat cancers; however, predicting their therapeutic efficacy remains challenging. The most commonly used predictive tests involve determining the in vitro susceptibility of a tumor's malignant cells to infection with an oncolytic agent. Whether these tests are truly predictive of in vivo efficacy, however, remains unclear. Here we demonstrate that a recombinant, oncolytic myxoma virus shows efficacy in two murine models of triple negative breast cancer despite extremely low permissivity of these models to viral infection. These data demonstrate that in vitro infectivity studies are not an accurate surrogate for therapeutic efficacy and suggest that other tests need to be developed.
期刊介绍:
Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.